All questions
Pharmacology: Skyrizi (risankizumab-rzaa) in plaque psoriasis 3 questions · 2 sources
Pharmacology questions that apply to every indication of Skyrizi are on Skyrizi (risankizumab-rzaa), all indications: Pharmacology .
Mechanism How does Skyrizi work (mechanism of action)? Pharmacokinetics How long does Skyrizi stay in your system (half-life)? Components What are the inactive ingredients in Skyrizi? “SKYRIZI (risankizumab-rzaa) injection 55 mg/0.37 mL prefilled syringe for subcutaneous use
Each SKYRIZI prefilled syringe contains a sterile, preservative-free, colorless to yellow, and
clear to slightly opalescent solution. Each syringe delivers 55 mg of risankizumab-rzaa and the
inactive ingredients glacial acetic acid (0.02 mg), polysorbate 20 (0.07 mg), sodium acetate
(0.28 mg), trehalose (23.4 mg), and Water for Injection, USP. The pH is 5.7.
SKYRIZI (risankizumab-rzaa) injection 150 mg/mL prefilled syringe or prefilled pen for
subcutaneous use
Each SKYRIZI prefilled pen or prefilled syringe contains a sterile, preservative-free, colorless to
yellow, and clear to slightly opalescent solution. Each syringe and pen delivers 150 mg of
risankizumab-rzaa and the inactive ingredients glacial acetic acid (0.054 mg), polysorbate 20
(0.2 mg), sodium acetate (0.75 mg), trehalose (63.33 mg), and Water for Injection, USP. The pH
is 5.7.” (opens the source at this quote in a new tab) Copy Flag
Note: The first passage, from the Medication Guide, covers every presentation. The second gives the amounts per unit for the presentations used for plaque psoriasis: the 55 mg/0.37 mL prefilled syringe and the 150 mg/mL prefilled pen and syringe.